{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:54:30Z","timestamp":1767650070031,"version":"3.33.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2000,5,1]],"date-time":"2000-05-01T00:00:00Z","timestamp":957139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2000,5]]},"DOI":"10.1007\/s11940-000-0003-4","type":"journal-article","created":{"date-parts":[[2007,6,4]],"date-time":"2007-06-04T17:43:56Z","timestamp":1180979036000},"page":"205-213","source":"Crossref","is-referenced-by-count":23,"title":["Tardive dyskinesia"],"prefix":"10.1007","volume":"2","author":[{"given":"Daniel","family":"Tarsy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"3_CR1","doi-asserted-by":"crossref","first-page":"38S","DOI":"10.1097\/00004714-198808001-00008","volume":"8","author":"DV Jeste","year":"1988","unstructured":"Jeste DV, Lohr JB, Clark K, et al.: Pharmacological treatments of tardive dyskinesia in the 1980\u2019s. J Clin Psychopharmacol 1988, 8:38S-48S.","journal-title":"J Clin Psychopharmacol"},{"key":"3_CR2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.870010305","volume":"1","author":"UJ Kang","year":"1986","unstructured":"Kang UJ, Burke RE, Fahn S: Natural history and treatment of tardive dystonia. Mov Disord 1986, 1:193\u2013208. This is an excellent review of a single center\u2019s experience with tardive dystonia.","journal-title":"Mov Disord"},{"key":"3_CR3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/00002826-199702000-00012","volume":"20","author":"D Tarsy","year":"1997","unstructured":"Tarsy D, Kaufman D, Sethi KD, et al.: An open-label study of botulinum toxin A for treatment of tardive dystonia. Clin Neuropharmacol 1997, 20:90\u201393. This is the first large series of patients with tardive dystonia treated with botulinum toxin.","journal-title":"Clin Neuropharmacol"},{"key":"3_CR4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00002826-199506000-00001","volume":"18","author":"J Jankovic","year":"1995","unstructured":"Jankovic J: Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 1995, 18:197\u2013214. An excellent overview of variants of TD is presented.","journal-title":"Clin Neuropharmacol"},{"key":"3_CR5","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1176\/ajp.151.6.836","volume":"151","author":"G Gardos","year":"1994","unstructured":"Gardos G, Casey DE, Cole JO, et al.: Ten-year outcome of tardive dyskinesia. Am J Psychiatry 1994, 151:836\u2013841.","journal-title":"Am J Psychiatry"},{"key":"3_CR6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00002826-198306000-00003","volume":"6","author":"D Tarsy","year":"1983","unstructured":"Tarsy D: History and definition of tardive dyskinesia. Clin Neuropharmacol 1983, 6:91\u201399.","journal-title":"Clin Neuropharmacol"},{"key":"3_CR7","first-page":"486","volume":"39","author":"NR Schooler","year":"1982","unstructured":"Schooler NR, Kane JM: Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982, 39:486\u2013487.","journal-title":"Arch Gen Psychiatry"},{"key":"3_CR8","first-page":"75","volume-title":"Movement Disorders in Neurology and Neuropsychiatry","author":"D Tarsy","year":"1999","unstructured":"Tarsy D: Akathisia. In Movement Disorders in Neurology and Neuropsychiatry, edn 2. Edited by Joseph AB, Young RR. Boston: Blackwell; 1999:75\u201383.","edition":"edn 2"},{"key":"3_CR9","first-page":"29","volume-title":"Clinical Neuropharmacology","author":"D Tarsy","year":"1976","unstructured":"Tarsy D, Baldessarini RJ: The tardive dyskinesia syndrome. In Clinical Neuropharmacology, vol 1. Edited by Klawans HL. New York: Raven Press; 1976:29\u201361."},{"key":"3_CR10","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archpsyc.1982.04290040069010","volume":"39","author":"JM Kane","year":"1982","unstructured":"Kane JM, Smith JM: Tardive dyskinesia. Prevalence and risk factors, 1959\u20131979. Arch Gen Psychiatry 1982, 39:473\u2013481. This is an excellent meta-analysis that established the accepted prevalence figures for tardive dyskinesia and spontaneous dyskinesia.","journal-title":"Arch Gen Psychiatry"},{"key":"3_CR11","first-page":"387","volume":"20","author":"JM Kane","year":"1984","unstructured":"Kane JM, Woerner M, Weinhold P: Incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacol Bull 1984, 20:387\u2013389. This is the first prospective study establishing incidence figures for tardive dyskinesia.","journal-title":"Psychopharmacol Bull"},{"key":"3_CR12","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/archpsyc.1980.01780250054006","volume":"37","author":"JM Smith","year":"1980","unstructured":"Smith JM, Baldessarini RJ: Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry 1980, 37:1368\u20131373.","journal-title":"Arch Gen Psychiatry"},{"key":"3_CR13","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1176\/ajp.147.4.445","volume":"147","author":"GK Thaker","year":"1990","unstructured":"Thaker GK, Nguyen JA, Strauss ME, et al.: Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry 1990, 147:445\u2013451.","journal-title":"Am J Psychiatry"},{"key":"3_CR14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1176\/ajp.138.2.189","volume":"138","author":"A Bobruff","year":"1981","unstructured":"Bobruff A, Gardos G, Tarsy D, et al.: Clonazepam and phenobarbital in tardive dyskinesia. Am J Psychiatry 1981, 138:189\u2013193.","journal-title":"Am J Psychiatry"},{"key":"3_CR15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/bmj.4.5778.25","volume":"2","author":"RB Godwin-Austen","year":"1971","unstructured":"Godwin-Austen RB, Clark T: Persistent phenothiazine dyskinesia treated with tetrabenazine. Br Med J 1971, 2:25\u201326.","journal-title":"Br Med J"},{"key":"3_CR16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.1972.01750250081011","volume":"27","author":"H Kazamatsuri","year":"1972","unstructured":"Kazamatsuri H, Chien C, Cole JO: Treatment of tardive dyskinesia. Arch Gen Psychiatry 1972, 27:95\u201399.","journal-title":"Arch Gen Psychiatry"},{"key":"3_CR17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1176\/ajp.130.4.479","volume":"130","author":"H Kazamatsuri","year":"1973","unstructured":"Kazamatsuri H, Chien C, Cole JO: Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry 1973, 130:479\u2013483.","journal-title":"Am J Psychiatry"},{"key":"3_CR18","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.48.2.358","volume":"48","author":"J Jankovic","year":"1997","unstructured":"Jankovic J, Beach J: Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997, 48:358\u2013362.","journal-title":"Neurology"},{"key":"3_CR19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00002826-198212000-00005","volume":"5","author":"AE Lang","year":"1982","unstructured":"Lang AE, Marsden CD: Alphamethylparatyrosine and tetrabenazine in movement disorders. Clin Neuropharmacol 1982, 5:375\u2013387.","journal-title":"Clin Neuropharmacol"},{"key":"3_CR20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF00426466","volume":"73","author":"CC Huang","year":"1981","unstructured":"Huang CC, Wang RIH, Hasegawa A, et al.: Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia. Psychopharmacology 1981, 73:359\u2013362.","journal-title":"Psychopharmacology"},{"key":"3_CR21","first-page":"680","volume":"32","author":"S Sato","year":"1971","unstructured":"Sato S, Daly R, Peters H: Reserpine therapy of phenothiazine induced dyskinesia. Dis Nerv Syst 1971, 32:680\u2013684.","journal-title":"Dis Nerv Syst"},{"key":"3_CR22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00004714-199906000-00017","volume":"19","author":"T Suzuki","year":"1999","unstructured":"Suzuki T, Hori T, Baba A, et al.: Effectiveness of anticholinergics and neuroleptic dose reduction on neuroleptic-induced pleurothotonus (Pisa syndrome). J Clin Psychopharmacol 1999, 19:277\u2013280.","journal-title":"J Clin Psychopharmacol"},{"key":"3_CR23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.158.4.503","volume":"158","author":"JA Lieberman","year":"1991","unstructured":"Lieberman JA, Saltz BL, Johns CA, et al.: The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991, 158:503\u2013510. A thoughtful discussion of the role of clozapine in the management of tardive dyskinesia is presented.","journal-title":"Br J Psychiatry"},{"key":"3_CR24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4088\/JCP.v58n0706","volume":"58","author":"B Spivak","year":"1997","unstructured":"Spivak B, Mester R, Abesgaus J, et al.: Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997, 58:318\u2013322.","journal-title":"J Clin Psychiatry"},{"key":"3_CR25","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mds.870120403","volume":"12","author":"SA Factor","year":"1997","unstructured":"Factor SA, Friedman JH: The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997, 12:483\u2013496.","journal-title":"Mov Disord"},{"key":"3_CR26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00023210-199911060-00005","volume":"11","author":"H Fernandez","year":"1999","unstructured":"Fernandez H, Friedman JH: The role of atypical antipsychotics in the treatment of movement disorders. CNS Drugs 1999, 11:467\u2013483. This is an excellent review of the use of atypical neuroleptics in the treatment of movement disorders.","journal-title":"CNS Drugs"},{"key":"3_CR27","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1176\/ajp.150.9.1405","volume":"150","author":"LA Adler","year":"1993","unstructured":"Adler LA, Pesalow E, Rotrosen J, et al.: Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 1993, 150:1405\u20131407.","journal-title":"Am J Psychiatry"},{"key":"3_CR28","first-page":"925","volume":"159","author":"LM Dabiri","year":"1994","unstructured":"Dabiri LM, Pasta D, Darby JK, et al.: Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. Am J Psychiatry 1994, 159:925\u2013926.","journal-title":"Am J Psychiatry"},{"key":"3_CR29","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(87)92878-9","volume":"1","author":"JB Lohr","year":"1987","unstructured":"Lohr JB, Cadet JL, Lohr MA, et al.: Alpha-tocopherol in tardive dyskinesia. Lancet 1987, 1:913\u2013914.","journal-title":"Lancet"},{"key":"3_CR30","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1176\/ajp.149.6.773","volume":"149","author":"MF Eagen","year":"1992","unstructured":"Eagen MF, Hyde TM, Albers GW, et al.: Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 1992, 149:773\u2013777.","journal-title":"Am J Psychiatry"},{"key":"3_CR31","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/ajp.149.3.391","volume":"149","author":"CL Shriqui","year":"1992","unstructured":"Shriqui CL, Bradwejn J, Annabel L, et al.: Vitamin E and the treatment of tardive dyskinesia: a doubleblind placebo-controlled study. Am J Psychiatry 1992, 149:391\u2013393.","journal-title":"Am J Psychiatry"},{"key":"3_CR32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0006-3223(96)00367-8","volume":"41","author":"A Dorevitch","year":"1997","unstructured":"Dorevitch A, Kallian M, Shlafman M, et al.: Treatment of long-term tardive dyskinesia with vitamin E. Biol Psychiatry 1997, 41:114\u2013116.","journal-title":"Biol Psychiatry"},{"key":"3_CR33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00002018-199920020-00007","volume":"20","author":"G Gardos","year":"1999","unstructured":"Gardos G: Managing antipsychotic-induced tardive dyskinesia. Drug Safety 1999, 20:187\u2013193. An excellent review is presented with a useful algorithm for the management of tardive dyskinesia.","journal-title":"Drug Safety"},{"key":"3_CR34","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/mds.870130130","volume":"13","author":"A Brashear","year":"1998","unstructured":"Brashear A, Ambrosius WT, Eckert GJ, et al.: Comparison of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Mov Disord 1998, 13:158\u2013161.","journal-title":"Mov Disord"},{"key":"3_CR35","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(05)60203-6","volume":"349","author":"Y Wang","year":"1997","unstructured":"Wang Y, Turnbull I, Calne S, et al.: Pallidotomy for tardive dyskinesia. Lancet 1997, 349:777\u2013778.","journal-title":"Lancet"},{"key":"3_CR36","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/mds.870130415","volume":"13","author":"WG Ondo","year":"1998","unstructured":"Ondo WG, Desaloms JM, Jankovic J, et al.: Pallidotomy for generalized dystonia. Mov Disord 1998, 13:693\u2013698.","journal-title":"Mov Disord"},{"key":"3_CR37","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1176\/ajp.134.10.1149","volume":"134","author":"H Albanese","year":"1977","unstructured":"Albanese H, Gaarder K: Biofeedback treatment of tardive dyskinesia: two case reports. Am J Psychiatry 1977, 134:1149\u20131150.","journal-title":"Am J Psychiatry"},{"key":"3_CR38","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1176\/ajp.135.10.1248-a","volume":"135","author":"GM Asnis","year":"1978","unstructured":"Asnis GM, Leopold MA: A single-blind study of ECT in patients with tardive dyskinesia. Am J Psychiatry 1978, 135:1235\u20131236.","journal-title":"Am J Psychiatry"},{"key":"3_CR39","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1176\/ajp.137.10.1163","volume":"137","author":"Task Force on Late Neurological Effects of Antipsychotic Drugs","year":"1980","unstructured":"Task Force on Late Neurological Effects of Antipsychotic Drugs: Tardive dyskinesia: summary of a Task Force Report of the American Psychiatric Association. Am J Psychiatry 1980, 137:1163\u20131172.","journal-title":"Am J Psychiatry"},{"key":"3_CR40","unstructured":"Tardive Dyskinesia: a Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatry Association Press; 1992. This authoritative review is required reading for physicians who use antipsychotic drugs."}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-000-0003-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-000-0003-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-000-0003-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T22:27:58Z","timestamp":1737066478000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-000-0003-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,5]]}},"alternative-id":["3"],"URL":"https:\/\/doi.org\/10.1007\/s11940-000-0003-4","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"type":"print","value":"1092-8480"},{"type":"electronic","value":"1534-3138"}],"subject":[],"published":{"date-parts":[[2000,5]]}}}